Reuters logo
9 个月前
BRIEF-Kempharm receives clearance from FDA to initiate clinical program for KP201/IR
2016年11月29日 / 下午3点17分 / 9 个月前

BRIEF-Kempharm receives clearance from FDA to initiate clinical program for KP201/IR

Nov 29 (Reuters) - Kempharm Inc :

* Kempharm receives clearance from FDA to initiate clinical program for KP201/IR, a single-entity benzhydrocodone HCL immediate release abuse-deterrent prodrug for the treatment of acute pain

* Kempharm expects to conduct human clinical trials of KP201/IR in 2017

* Intend to initiate human clinical trials of KP201/IR in first half of 2017

* Remain on target for a potential submission in 2018 of KP201/IR new drug application Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below